switching from ozempic to retatrutide is an experimental peptide that outperforms by activating GLP-1, GIP, and glucagon pathways simultaneously, delivering nearly 30% average weight loss in clinical trials Switching From Tirzepatide to Retatrutide

Use of GLP-1/GIP Drops should be supervised by a qualified healthcare professional as part of a complete treatment approach

Similar effects on IL-1, IL-6, and IL-8 levels were observed when cells were treated with simvastatin, pravastatin, and the renin-angiotensin system inhibitors spironolactone, captopril, lisinopril, candesartan, and losartan

Overall, GLP-1-based therapies are rapidly gaining popularity: a staggering 1 in 8 US adults aged 18 years or older reports having used a GLP-1 analog medication (21)

This effect was previously documented in the DCCT and UKPDS trials and occurs regardless of the treatment method used (insulin, oral agents, or GLP-1 medications), reflecting changes in retinal blood flow and vascular permeability during metabolic adjustment

Mohan M, Al-Talabany S, McKinnie A, et al

Protecting Australians from unsafe compounding of replica weight loss products. Eli Lilly Australia